AMAP1 is an oncogene in various cancers, and high AMAP1 levels predict inferior outcomes in patients with triple-negative breast cancer (He et al., 2020), ovarian cancer (Hou et al., 2014), colorectal cancer (Muller et al., 2010), and laryngeal squamous cell carcinoma (Li et al., 2014). The gene discussed is ASAP1; the disease is ovarian carcinoma.